Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

• Status: Not yet recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the metachronous liver metastases of colorectal cancer. A one-arm randomized clinical trial was conducted, and the patients were grouped according to their treatment methods. The patients with metachronous liver metastases were used as the end point of the experiment to evaluate the blocking effect of quintuple therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Liaoning Tumor Hospital & Institute
• Treatments: Capecitabine; Cetuximab; Folic Acid; Metronidazole; Oxaliplatin; Vitamin A

Criteria

Inclusion Criteria:

1. Ages 18-80 at the time of signing the informed consent;

2. Histologically or cytologically confirmed adenocarcinoma of the colon or rectum;

3. Radical surgery has been performed;

4. Imaging examination showed no liver metastasis;

5. Prehepatic CTC number ≥1;

6. The ECOG performance status is 0-1.

7. No combination of other life-threatening diseases;

8. Willingness and ability to follow scheduled visits, treatment plans, laboratory tests and other research procedures.

Exclusion Criteria:

1. Patients with non-primary colorectal cancer;

2. Patients with liver metastasis or other organ metastasis;

3. Patients without prehepatic CTC or whose prehepatic CTC were negative;

4. People who are severely allergic to one or more of the drugs required in the test;

5. Patients with severe underlying diseases of respiratory, circulatory, urinary and hematopoietic systems.